Neuronetics Plans to Announce Financial Results
Neuronetics, Inc. (NASDAQ: STIM), a leader in the field of neurohealth technology, has exciting news as it prepares to share its financial and operating results for the third quarter of 2025. The company, based in Malvern, Pennsylvania, has made significant strides in its offerings, particularly with its flagship product, NeuroStar Advanced Therapy, which provides non-invasive treatment options for patients dealing with mental health disorders.
Details of the Upcoming Conference Call
Scheduled to occur before the market opens on November 4, 2025, this conference call aims to discuss the financial performance and operational highlights from the quarter. The call will be available through a live webcast, allowing stakeholders to join from anywhere. Attendees are encouraged to log in early to ensure they do not miss any part of the discussion, which will provide insights into the company’s financial state and future strategies.
Webcast Accessibility
For those interested in participating, the webcast will be hosted securely, with options to join via phone for a more personal connection. By pre-registering, participants can easily add this important event to their calendars. The gathering promises to be informative, shedding light on Neuronetics’ financial health and strategic direction.
About NeuroStar Advanced Therapy
Neuronetics has positioned itself as a frontrunner in transforming mental health care through innovative technologies. The company’s NeuroStar Advanced Therapy is particularly noteworthy, recognized for its effectiveness as a non-drug treatment for major depressive disorder (MDD). Patients who have not found relief through traditional means often turn to this solution, which utilizes Transcranial Magnetic Stimulation (TMS) to alleviate symptoms.
Expanding Treatment Options
Not only has NeuroStar become a key player in TMS therapy, but Neuronetics also operates through Greenbrook TMS centers across the nation. These facilities are dedicated to providing access to NeuroStar Advanced Therapy, assisting more than 55,000 patients with over 1.8 million treatments delivered. This extensive reach underscores the company’s commitment to improving mental health outcomes through innovative, patient-centered care.
Future Outlook and Industry Contributions
Looking forward, Neuronetics aims to continue expanding its influence in the mental health sector. With an increasing awareness of the importance of mental health on overall well-being, the demand for effective treatment options is rising. Neuronetics strives to meet this need, focusing on research and development to enhance existing treatments and explore new possibilities.
Community Commitment
Moreover, the company’s dedication to mental health goes hand-in-hand with their commitment to the community. By partnering with healthcare providers and investing in educational resources, Neuronetics is fostering a more informed public about the options available for managing mental health conditions.
Investor Relations and Contact Information
For investors looking for further information, Neuronetics provides a pathway to stay updated through their investor relations contacts. Mike Vallie and Mark Klausner from ICR Healthcare are available to address any inquiries, ensuring that stakeholders receive timely updates regarding the company’s forward movement and market activities.
Media Engagement
Media inquiries can be directed to EvolveMKD, which assists Neuronetics in communicating their advancements and contributions in healthcare innovation. Media contacts are always eager to share the positive impacts the company strives to deliver through its technologies.
Frequently Asked Questions
What is the purpose of the upcoming conference call?
The conference call will address Neuronetics' financial and operating results for Q3 2025 and outline future strategies.
How can I participate in the conference call?
Participants can join via a live webcast or by phone, with recommendations to register in advance for a seamless experience.
What is NeuroStar Advanced Therapy?
NeuroStar Advanced Therapy is a non-invasive TMS treatment for major depressive disorder, providing an alternative option for patients.
How many treatments has NeuroStar provided?
The NeuroStar system has delivered over 7.6 million treatments to support patients battling depression.
Who can I contact for investor inquiries?
For investor-related questions, please contact Mike Vallie or Mark Klausner at ICR Healthcare.
